News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Celgene 3rd Quarter Profit Jumps on Revlimid Sales
October 23, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON, Oct. 23 (Reuters) - Celgene Corp said on Thursday that its third-quarter earnings rose on higher sales of its cancer drugs.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoffs
Appia, Former Kite Cell Therapy Collaborator, Shuts Down
August 26, 2025
·
2 min read
·
Tristan Manalac
IPO
Biotech Finally Has an IPO After Months-Long Freeze
August 25, 2025
·
1 min read
·
Annalee Armstrong
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
August 25, 2025
·
3 min read
·
Annalee Armstrong
Startups
Arnatar Debuts With $52M To Advance RNA Therapies That Go Beyond Silencing
August 25, 2025
·
2 min read
·
Tristan Manalac
